DLB
NYSEDOLBY LABORATORIES, INC.
Financial Services · Patent Owners & Lessors
Research view
Fundamentals · SEC EDGAR · FY 2025-09-26
Revenue & Earnings — fiscal year
$1.3B
2021
$1.3B
2022
$1.3B
2023
$1.3B
2024
$1.3B
2025
Snapshot
SEC EDGAR · FY 2025-09-26Revenue$1.3B
Net Income$256.5M
Gross Profit$1.2B
Oper Income$265.0M
EPS (dil)$2.62
Rev/sh—
FCF/sh—
Book/sh—
Gross M88.1%
Oper M19.6%
Profit M19.0%
FCF M32.3%
ROE9.7%
ROA7.9%
ROIC12.2%
R&D/Rev19.4%
Rev Y/Y5.9%
Rev 3Y CAGR2.5%
EPS Y/Y-2.6%
EPS 3Y CAGR13.1%
FCF 3Y CAGR17.2%
Payout49%
Div/sh$1.32
Shs Chg Y/Y+0.2%
Current Ratio3.17
Quick Ratio3.10
Debt/Eq—
Int Coverage672.5×
Net Debt—
Total Debt—
Cash & Eq$793.4M
Total Assets$3.2B
Oper CF$472.2M
Capex$36.3M
Free CF$435.9M
Buybacks$125.0M
Equity$2.6B
Liabilities$595.8M
Shs Outstand—
SectorFinancial Services
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B |
| Gross Profit | $1.2B | $1.1B | $1.1B | $1.1B | $1.2B |
| Operating Income | $344.4M | $206.6M | $215.8M | $258.3M | $265.0M |
| Net Income | $317.8M | $183.9M | $201.6M | $264.3M | $256.5M |
| Diluted EPS | $2.97 | $1.81 | $2.05 | $2.69 | $2.62 |
| Operating Cash Flow | $447.8M | $318.6M | $367.1M | $327.3M | $472.2M |
| Free Cash Flow | $393.3M | $270.6M | $336.7M | $297.2M | $435.9M |
COMMUNITY · $DLB0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.